Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
1924
mi
from 91732
Decatur, GA
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
1924
mi
from 91732
Decatur, GA
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
941
mi
from 91732
Coeur D Alene, ID
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
941
mi
from 91732
Coeur D Alene, ID
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
1720
mi
from 91732
Park Ridge, IL
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
1720
mi
from 91732
Park Ridge, IL
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
1580
mi
from 91732
Bettendorf, IA
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
1580
mi
from 91732
Bettendorf, IA
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
1335
mi
from 91732
Overland Park, KA
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
1335
mi
from 91732
Overland Park, KA
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
1813
mi
from 91732
Louisville, KY
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
1813
mi
from 91732
Louisville, KY
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
2301
mi
from 91732
Baltimore, MD
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
1524
mi
from 91732
Rochester, MN
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
1524
mi
from 91732
Rochester, MN
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
1609
mi
from 91732
Jackson, MS
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
1609
mi
from 91732
Jackson, MS
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
1333
mi
from 91732
St. Joseph, MO
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
1333
mi
from 91732
St. Joseph, MO
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
218
mi
from 91732
Henderson, NV
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
218
mi
from 91732
Henderson, NV
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
2515
mi
from 91732
Lebanon, NH
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
2515
mi
from 91732
Lebanon, NH
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
2423
mi
from 91732
Newark, NJ
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
2423
mi
from 91732
Newark, NJ
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
2435
mi
from 91732
New York, NY
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
2002
mi
from 91732
Ashville, NC
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
2002
mi
from 91732
Ashville, NC
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
2032
mi
from 91732
Cleveland, OH
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
2032
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
1253
mi
from 91732
Tulsa, OK
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
1253
mi
from 91732
Tulsa, OK
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
2375
mi
from 91732
Philadelphia, PA
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
2184
mi
from 91732
Charleston, SC
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
2184
mi
from 91732
Charleston, SC
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
1853
mi
from 91732
Chattanooga, TN
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
1853
mi
from 91732
Chattanooga, TN
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
1225
mi
from 91732
Dallas, TX
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
1225
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
2336
mi
from 91732
Norfolk, VA
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
2336
mi
from 91732
Norfolk, VA
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
964
mi
from 91732
Seattle, WA
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
964
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Clinical Research Facility
1722
mi
from 91732
Milwaukee, WI
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Clinical Research Facility
1722
mi
from 91732
Milwaukee, WI
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Mobile Diagnostic Center Rheumatology
1757
mi
from 91732
Mobile, AL
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Mobile Diagnostic Center Rheumatology
1757
mi
from 91732
Mobile, AL
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Valerius Medical Group
23
mi
from 91732
Long Beach, CA
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Valerius Medical Group
23
mi
from 91732
Long Beach, CA
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Trial Concierge/Pacific Clinical Studies
19
mi
from 91732
Los Alamitos, CA
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Trial Concierge/Pacific Clinical Studies
19
mi
from 91732
Los Alamitos, CA
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Axis Clinical Trials
19
mi
from 91732
Los Angeles, CA
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Axis Clinical Trials
19
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Riverside Clinical Research
2201
mi
from 91732
Edgewater, FL
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Riverside Clinical Research
2201
mi
from 91732
Edgewater, FL
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Global Clinical Professionals
2320
mi
from 91732
Miami, FL
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Global Clinical Professionals
2320
mi
from 91732
Miami, FL
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
The Arthritis Center
2117
mi
from 91732
Palm Harbor, FL
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
The Arthritis Center
2117
mi
from 91732
Palm Harbor, FL
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Lakeview Medical Research
2135
mi
from 91732
Summerfield, FL
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Lakeview Medical Research
2135
mi
from 91732
Summerfield, FL
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Analan Clinical Research
1331
mi
from 91732
Lenexa, KA
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Analan Clinical Research
1331
mi
from 91732
Lenexa, KA
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Trial Concierge
1739
mi
from 91732
Owensboro, KY
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Trial Concierge
1739
mi
from 91732
Owensboro, KY
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Quality Clinical Research, Inc.
1295
mi
from 91732
Omaha, NE
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Quality Clinical Research, Inc.
1295
mi
from 91732
Omaha, NE
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Advanced Biomedical Research of America
212
mi
from 91732
Las Vegas, NV
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Advanced Biomedical Research of America
212
mi
from 91732
Las Vegas, NV
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Arthritis Center of Reno
389
mi
from 91732
Reno, NV
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Arthritis Center of Reno
389
mi
from 91732
Reno, NV
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Pmg Research Of Salisbury
2118
mi
from 91732
Salisbury, NC
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Pmg Research Of Salisbury
2118
mi
from 91732
Salisbury, NC
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Providence Health Partners
1897
mi
from 91732
Dayton, OH
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Providence Health Partners
1897
mi
from 91732
Dayton, OH
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Paramount Medical Research & Consulting, Llc
2025
mi
from 91732
Middleburg Heights, OH
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Paramount Medical Research & Consulting, Llc
2025
mi
from 91732
Middleburg Heights, OH
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
The Center for Excellence in Aging and Geriatric Health
2311
mi
from 91732
Williamsburg, VA
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
The Center for Excellence in Aging and Geriatric Health
2311
mi
from 91732
Williamsburg, VA
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
Apex Clinical Research
840
mi
from 91732
Kennewick, WA
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
Apex Clinical Research
840
mi
from 91732
Kennewick, WA
Click here to add this to my saved trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated:  11/1/2012
South Puget Sound Clinical Research Center
931
mi
from 91732
Olympia, WA
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis
Status: Enrolling
Updated: 11/1/2012
South Puget Sound Clinical Research Center
931
mi
from 91732
Olympia, WA
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
1784
mi
from 91732
Birmingham, AL
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
1784
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
343
mi
from 91732
Phoenix, AZ
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
343
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
316
mi
from 91732
Santa Clara, CA
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
316
mi
from 91732
Santa Clara, CA
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
2473
mi
from 91732
Bridgeport, CT
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
2473
mi
from 91732
Bridgeport, CT
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
2354
mi
from 91732
Newark, DE
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
2354
mi
from 91732
Newark, DE
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
2187
mi
from 91732
Daytona Beach, FL
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
2187
mi
from 91732
Daytona Beach, FL
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
1924
mi
from 91732
Decatur, GA
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
1924
mi
from 91732
Decatur, GA
Click here to add this to my saved trials